Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers
Research into novel therapies for gynecologic cancers is underfunded, and as a result, we are still playing catchup with other solid tumors in the realm of immune checkpoint inhibition. This is despite the fact that two of the most common gynecologic cancers in the USA have strong biologic rationales for response to these agents. Work is now underway to demonstrate safe and effective therapies for our patients. As we better understand the immune system, and more specifically the tumor microenvironment, we will be able to achieve complete responses. The immune system can learn, adapt, and provide ongoing surveillance; if only we could mimic its abilities.
KeywordsLynch syndrome Gynecologic cancers Immunotherapy Checkpoint inhibitors Endometrial cancer Ovarian cancer PD-1 PD-L1
Compliance with Ethical Standards
Conflict of Interest
The authors declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 12.McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, Rodgers WH, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a gynecologic oncology group study. Gynecol Oncol. 2007;106(1):16–22.CrossRefGoogle Scholar
- 18.Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology. 2017;6(2):e1264565.CrossRefGoogle Scholar
- 20.•• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13 Established checkpoint inhibitors as a therapeutic option for dMMR tumors, regardless of tissue of origin.CrossRefGoogle Scholar
- 23.Fuh K, Lomonosova E, Guo L, Fantl W, Pachynski R, Malkova O, et al. Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial cancer. ASCO Annual Meeting; June 1, 2019; Chicago, IL. J Clin Oncol. 2019;37(suppl; abstr 5590).CrossRefGoogle Scholar
- 25.Santin AD. Pembrolizumab in ultramutated and hypermutated endometrial cancer. NCT02899793. ClinicalTrials.gov: NCI; [Available from: https://clinicaltrials.gov/ct2/show/NCT02899793?term=02899793&rank=1. Accessed 14 June 2019.
- 27.Makker V, Herraez A, Aghajanian C, Fujiwara K, Pignata S, Penson RT, et al. A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer. ASCO Annual Meeting; June 1, 2019; Chicago, IL. J Clin Oncol. 2019;37(suppl; abstr TPS5607).CrossRefGoogle Scholar
- 28.Eskander RN, NRG-Oncology. Testing the addition of the immunotherapy drug pembrolizumab to the usual chemotherapy treatment (paclitaxel and carboplatin) in stage iii-iv or recurrent endometrial cancer, NCT03914612. clinicaltrials.gov: NCI; [Available from: https://clinicaltrials.gov/ct2/show/NCT03914612?term=03914612&rank=1. Accessed 14 June 2019.
- 31.Antill Y, Kok P, Robledo K, Barnes E, Friedlander M, Baron-Hay S, et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). ASCO Annual Meeting; June 3, 2019; Chicago, IL. J Clin Oncol. 2019;37(suppl; abstr 5501).CrossRefGoogle Scholar
- 32.Konstantinopoulos PA, Liu JF, Luo W, Krasner CN, Ishizuka J, Gockley A, et al. Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC). ASCO Annual Meeting; June 3, 2019; Chicago, IL. J Clin Oncol. 2019;37(suppl;abstr 5502).Google Scholar
- 33.Colombo N, Barretina-Ginesta M, Beale P, Harano K, Hudson E, Marme F, et al. AtEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. . ASCO Annual Meeting; June 1, 2019; Chicago, IL. J Clin Oncol. 2019;37(suppl; abst TPS5608).Google Scholar
- 34.Rubinstein M, Caird I, Zhou Q, Iasonos A, Friedman C, Cadoo K, et al. A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma. . ASCO Annual Meeting June 1, 2019; Chicago, IL J Clin Oncol. 2019;37(suppl; abstr 5582).CrossRefGoogle Scholar
- 36.Antomarchi J, Ambrosetti D, Cohen C, Delotte J, Chevallier A, Karimdjee-Soilihi B, Ngo-Mai M, Schmid-Alliana A, Schmid-Antomarchi H. Immunosuppressive tumor microenvironment status and histological grading of endometrial carcinoma. Cancer Microenviron. 2019.Google Scholar
- 43.Lee L, Matulonis U. Immunotherapy and radiation combinatorial trials in gynecologic cancer: a potential synergy? Gynecol Oncol. 2019.Google Scholar
- 45.Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, Massuger LFAG, Snijders MPML, Kommoss S, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol. 2019.Google Scholar
- 48.•• Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks CB, et al. Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin Cancer Res. 2019;25(8):2537–48 A remarkable paper that further demonstrated the utility of the ProMisE classification of endometrial cancers, as well as the significance of TILs in the microenvironment.CrossRefGoogle Scholar
- 51.• Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–22 Demonstrated the use of checkpoint inhibitors in ovarian cancer.CrossRefGoogle Scholar
- 52.Hamanishi J, Murakami R, Baba T, Yamaguchi K, Abiko K, Mandai M. Passenger fusion genes are correlated to antitumor effect of anti-PD-1 antibody nivolumab for ovarian cancer. 2019 SGO annual meeting; march 2019; Honolulu, HI.Google Scholar
- 58.Pujade-Lauraine E, Fujiwarab K, Ledermann JA, Oza A, Kristeleit R, Ray-Coquard I, et al. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. 2019 SGO Annumal meeting; march 17, 2019; Honolulu, HI.Google Scholar
- 59.Liao JB, Gwin W, Urban R, Hitchcock-Bernhardt K, Coveler A, Higgins D, et al. Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results. 2019 ASCO annual meeting; Chicago, IL. J Clin Oncol. 2019;37(suppl; abstr 5519).CrossRefGoogle Scholar
- 60.Moore KN, Pignata S. Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer. 2019.Google Scholar
- 62.Penn C, Lester J, Bohrer K, Moon C, Yearley J, Karlan BY, et al. PD-1/PD-L1 expression in BRCA1/2 mutated ovarian cancers. 2019 SGO annual meeting march 2019; Honolulu, HI.Google Scholar
- 64.Monk BJ, Coleman RL, Fujiwara K, Oza AM, Westin SN, O’Malley DM, et al. ATHENA (GOG-3020/ENGOT-ov45): a randomised, double-blind, placebo-controlled, phase 3 study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer. 2018 International Gynecologic Cancer Society Biennial Meeting; Kyoto, Japan.Google Scholar